Stock Price

With massive acquisitions in Florida and beyond, PACS Group is growing at a breakneck pace. But is its REIT-fueled, 'locally led' model a new paradigm for care or a risky bet?

Granted a 180-day Nasdaq extension, AI infrastructure firm Alpha Compute must now prove its high-tech vision is more than a penny stock reality.

In a feat of operational innovation, ACG Metals transformed a Turkish gold mine into a copper producer, timing its entry perfectly with the energy transition.

Gaming giant GDEV is buying back $20M of its own shares amid falling revenue. Is this a bold signal of confidence or a defensive move in a tough market?

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

Affirm crushes earnings estimates with a 1,300% EPS surprise, sending shares soaring. A deep dive into the BNPL leader's strategy and what it means for consumers.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

Capstone retired 75% of its dilutive convertible notes, a major milestone. But with a low stock price and reliance on an equity line, is this a true pivot?

As Ibotta executives head to Wall Street, the real story isn't just their financials, but how their pay-for-sale network is rewriting CPG marketing rules.

Interpace Biosciences is engineering its stock for a Nasdaq uplist, but is this financial maneuver a path to sustained growth or a classic warning sign?

As Nasdaq threatens delisting, Hub Group's $870M meltdown reveals more than accounting errors—it's a stark lesson in corporate governance.

AstroNova's move to go private via a buyout by Arcline Investment Management is more than a premium exit; it's a strategic play in the high-stakes world of mission-critical industrial technology.

A routine tender offer extension for a small healthcare operator reveals a larger story of a struggling company, a persistent buyer, and a new regulatory era.

A HK$120M venture signals a major shift in the GBA's cold chain. We dissect the tech, the money, and the competitive risks of this ambitious play.

Abundia's new stock buyback isn't just about shareholder value. It's a complex maneuver to restructure debt, fight off market skepticism, and ensure survival.

loanDepot touts major operational growth, yet its stock faces delisting from the NYSE. A deep dive into the company's fight for survival.

Andersen Group insiders cashed out $216.8M in a secondary offering. The company saw no cash, but the move signals market confidence and reshapes its future.

Vertical farming pioneer Agroz Inc. faces expulsion from Nasdaq, a crisis that exposes the harsh financial realities behind the promising agritech revolution.

Tactical Resources debuts on Nasdaq, promising a 'clean' path to rare earth security. But can its Texas project rewrite the rules for a toxic industry?

With shares in OpenAI and a huge stash of Worldcoin, Eightco is buying back its stock. Is it a signal of deep value or a high-risk bet on the AI future?